Barclays PLC Monte Rosa Therapeutics, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 70,741 shares of GLUE stock, worth $479,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,741

Previous 54,508 29.78%

Holding current value

$479,623

Previous $289,000 69.9%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$4.8 - $10.36 $77,918 - $168,173	16,233 Added 29.78%	70,741 $491,000
Q3 2024 Nov 15, 2024	BUY	$3.59 - $6.97 $156,161 - $303,188	43,499 Added 395.12%	54,508 $289,000
Q2 2024 Aug 14, 2024	SELL	$3.38 - $7.86 $36,297 - $84,408	-10,739 Reduced 49.38%	11,009 $41,000
Q1 2024 May 15, 2024	SELL	$4.26 - $8.46 $168,355 - $334,339	-39,520 Reduced 64.5%	21,748 $154,000
Q4 2023 Feb 15, 2024	BUY	$2.5 - $5.93 $120,242 - $285,215	48,097 Added 365.17%	61,268 $346,000
Q3 2023 Nov 07, 2023	SELL	$4.78 - $7.22 $2,217 - $3,350	-464 Reduced 3.4%	13,171 $63,000
Q2 2023 Aug 03, 2023	SELL	$4.53 - $8.4 $6,949 - $12,885	-1,534 Reduced 10.11%	13,635 $94,000
Q1 2023 May 04, 2023	BUY	$5.95 - $8.21 $42,726 - $58,956	7,181 Added 89.9%	15,169 $118,000
Q4 2022 Feb 13, 2023	BUY	$6.71 - $9.72 $45,440 - $65,823	6,772 Added 556.91%	7,988 $61,000
Q3 2022 Nov 03, 2022	SELL	$7.17 - $12.16 $1,606 - $2,723	-224 Reduced 15.56%	1,216 $10,000
Q2 2022 Aug 12, 2022	SELL	$6.15 - $14.99 $47,158 - $114,943	-7,668 Reduced 84.19%	1,440 $14,000
Q1 2022 May 16, 2022	BUY	$10.36 - $20.41 $94,358 - $185,894	9,108 New	9,108 $128,000

Others Institutions Holding GLUE

# of Institutions

102

Shares Held

49.1M

Call Options Held

285K

Put Options Held

31.2K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $317M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account